{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"0.52","value":"0.03"},{"groupId":"OG001","lowerLimit":"0.07","upperLimit":"0.50","value":"0.13"},{"groupId":"OG002","lowerLimit":"0.02","upperLimit":"0.47","value":"0.04"},{"groupId":"OG003","lowerLimit":"0.02","upperLimit":"0.07","value":"0.04"},{"groupId":"OG004","lowerLimit":"0.00","upperLimit":"1.00","value":"0.29"},{"groupId":"OG005","lowerLimit":"0.00","upperLimit":"0.65","value":"0.12"},{"groupId":"OG006","lowerLimit":"0.03","upperLimit":"1.00","value":"0.06"},{"groupId":"OG007","lowerLimit":"0.15","upperLimit":"0.18","value":"0.17"},{"groupId":"OG008","lowerLimit":"0.02","upperLimit":"1.00","value":"0.22"},{"groupId":"OG009","lowerLimit":"0.07","upperLimit":"0.08","value":"0.08"},{"groupId":"OG010","lowerLimit":"0.02","upperLimit":"0.50","value":"0.29"},{"groupId":"OG011","lowerLimit":"0.02","upperLimit":"1.00","value":"0.08"},{"groupId":"OG012","lowerLimit":"0.05","upperLimit":"0.50","value":"0.30"},{"groupId":"OG013","lowerLimit":"0.00","upperLimit":"1.02","value":"0.03"},{"groupId":"OG014","lowerLimit":"0.02","upperLimit":"0.48","value":"0.05"},{"groupId":"OG015","lowerLimit":"0.00","upperLimit":"0.52","value":"0.05"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"5"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"21"},{"groupId":"OG015","value":"16"},{"groupId":"OG016","value":"0"}],"units":"Participants"}],"description":"Time of Peak Plasma Concentration (Tmax)","dispersionType":"Full Range","groups":[{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG000","title":"Dose Regimen A (DR-A) Escalation (0.16 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG001","title":"Dose Regimen A (DR-A) Escalation (0.32 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG002","title":"Dose Regimen A (DR-A) Escalation (0.64 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG003","title":"Dose Regimen A (DR-A) Escalation (1.25 mg/kg) Escalation"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG004","title":"Dose Regimen A (DR-A) Escalation (2.10 mg/kg) Escalation"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG005","title":"Dose Regimen A (DR-A) Escalation (3.10 mg/kg) Escalation"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG006","title":"Dose Regimen A (DR-A) Escalation (4.40 mg/kg) Escalation"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG007","title":"Dose Regimen B (DR-B) Escalation (0.32 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG008","title":"Dose Regimen B (DR-B) Escalation (0.53 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG009","title":"Dose Regimen B (DR-B) Escalation (0.80 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG010","title":"Dose Regimen B (DR-B) Escalation (1.10 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG011","title":"Dose Regimen B (DR-B) Escalation (1.50 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG012","title":"Dose Regimen B (DR-B) Escalation (2.00 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG013","title":"Dose Regimen B (DR-B) Escalation (2.70 mg/kg)"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG014","title":"Dose Regimen A (DR-A) PTCL Expansion"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG015","title":"Dose Regimen C (DR-C) PTCL Expansion"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle Drug: Palbociclib Fixed-dose capsule administered orally on days 1 through 21 of a 28-day cycle ALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG016","title":"Combination With Palbociclib Expansion"}],"paramType":"MEDIAN","populationDescription":"The Pharmacokinetic Analysis Population included all subjects who received at least one dose of ALRN-6924 with sufficient plasma sample data to assess PK parameters, and with no major protocol violations. Plasma samples for subjects in the Combination With Palbociclib Expansion arm were collected but will not be processed or analyzed due to a protocol-level decision for this expansion arm to discontinue pharmacokinetic data collection.","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"Determine Pharmacokinetic Parameters of ALRN-6924 When Administered to Patients With Advanced Solid Tumors or Lymphomas","type":"SECONDARY","unitOfMeasure":"hour"}